Menu

A DRUG REGIMEN
AVAILABLE IN A NEW
BLISTER PACK

PACKAGING THAT'S MADE FOR LIVING

People Living with HIV (PLHIV) experiencing HIV-related stigma were 32% less likely to adhere to ART vs. those not reporting stigma (n=3984).†[1,2] Discreet packaging aims to reduce attention to the person’s medication, and together with indicators for the days of the week, could help PLHIV keep their medication on track.

†Association identified in a meta-analysis conducted in 3984 PLHIV from a total of 7 studies controlled for potential confounders.

Each Box of DOVATO (dolutegravir, lamivudine) contains 30 Tablets, Packaged into 5 blister packs (4 packs of 7 tablets and 1 pack of 2 tablets) cards, which are 79mm x 55mm x 6.7mm

Discreet

It’s small – a smaller surface than a credit card, meaning it can easily fit into your patient’s pocket, so your patients can easily carry it with them wherever they go.

Practical

Labelled for the days of the week, each blister strip can help your patients remember their medication and stick to their routine.[3,4]

Convenient

With a perforated line, the pack can be torn to make it even smaller, adding more convenience for those weekends away.

CONTACT US FOR MORE INFORMATION AND RESOURCES AROUND DOVATO AND THE DOVATO BLISTER PACK

IN REAL-WORLD STUDIES, SIMPLIFICATION WAS ONE OF THE MOST COMMON REASONS FOR SWITCHING TO DOVATO[6,7,8]

ONE PILL, ONCE A DAY[5]

CAN BE TAKEN WITH OR WITHOUT FOOD[5]

NO TIME-OF-DAY RESTRICTIONS[5]

FAVOURABLE DRUG-DRUG INTERACTION (DDI) PROFILE, WITH FEWER ANTICIPATED DDIS THAN OTHER EACS-RECOMMENDED SINGLE PILL REGIMENS†[5]

  • Click to view DDIs

    There are no clinically significant interactions expected between DOVATO and 88% of 43 commonly prescribed non-ARVs medications as defined by EACS*[9]

    Adapted from EACS Guidelines, 2023.[9]

*Includes 43 non-ARVs across cardiovascular drugs, CNS drugs, anti-infectives and miscellaneous (e.g., antacids, PPIs, H2 blockers, methadone and St John’s wort). Included in EACS Guidelines as commonly co-prescribed or of particular clinical relevance. Original data source: University of Liverpool HIV drug interaction data.[9]

†Contraindicated with fampridine.[5,10]

Efficacy of DOVATO in treatment-naïve patients

See data from the GEMINI studies

Click here

Efficacy of DOVATO in virologically suppressed patients

See the data from the TANGO study

Click here

References:

  1. Rueda S et al. BMJ Open 2016; 6(7): 1–15.
  2. Rueda S et al. BMJ Open 2016; 6(7): 1–15. (Suppl Appendix)
  3. Muiruri C et al. Patient Prefer Adherence 2020; 14: 153–161.
  4. Tan B et al. SAGE Open Med 2017; 5: 1–9.
  5. DOVATO (dolutegravir, lamivudine) Summary of Product Characteristics.
  6. Calza L et al. J Antimicrob Chemother 2020; 75(11): 3327–3333;
  7. Tan M et al. HIV Med 2019; 20(9): 634–637;
  8. Silva Sombra I, et al. Braz J Infect Dis 2021;25(S1):101045
  9. European AIDS Clinical Society (EACS) Guidelines. Version 12.0 October 2023.
  10. TRIUMEQ (dolutegravir/abacavir/lamivudine) Summary of Product Characteristics.

PM-GB-DLL-WCNT-240001 | March 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.